Biotech Co.*
(Country; Symbol)		 Pharma Co.
(Country)		 Type/Product Area Terms/Details (Date)
Abraxis BioScience Inc. (ABII) Green Cross Corp. (Japan) Exclusive licensing agreement to commercialize Abraxane in Korea Green Cross will pay Abraxis an up-front fee and milestone payments, as well as royalties, following Korean approval of the drug (11/28)
Alba Therapeutics Corp.* Shire plc (UK) Commercialization agreement for outside the U.S. and Japan for gastrointestinal permeability inhibitor AT-1001 Alba receives $25M up front and may pick up $80M in clinical, regulatory and launchmilestones and $220M in sales-based milestones; Alba also stands to get royalties on ex-U.S. and ex-Japan sales; if the collaboration expands beyond gastro-intestinal indications, the company could get another $40M per indication (12/14)
Anesiva Inc (ANSV) Medical Futures Inc. (Canada) Agreement granting an exclusive license to Medical Futures for the marketing and distribution of Anesiva's Zingo powder intradermal injection system in Canada Medical Futures will be responsible for all regulatory filings, marketing, distribution and selling in Canada (12/11)
BioMimetic Therapeutics Inc. (BMTI) Luitpold Pharmaceuticals Inc. (subsidiary of Sankyo Co. Ltd.; Japan) Agreement for BioMimetic to sell rights to its marketed periodontal therapy, GEM21S The deal brings $30M to BioMimetic no later than 60 days after the papers are signed, then $6M within 18 months and $4M no later than the end of 2009; Luitpold also is paying $4M in cash from the sale of existing inventory, plus royalty payments (12/17)
Ceragenix Pharmaceuticals Inc. (OTC BB:CGXP) Dr. Reddy's Laboratories Inc. (India) Exclusive distribution and supply agreement to commercialize EpiCeram for dry skin conditions in the U.S. The agreement grants Dr. Reddy's exclusivity in the U.S. for distributing and marketing EpiCeram while Ceragenix will be responsible for manufacturing and supply; Ceragenix will receive undisclosed milestone payments, as well as royalties (11/19)
Gilead Sciences Inc. (GILD) Bristol-Myers Squibb Co. Agreement to commercialize Atripla in Europe for the treatment of virologically suppressed adults with HIV-1 infection The companies will share responsibility for commercializing the drug through the European Union and certain other European countries (12/11)
Neoprobe Corp. (OTC BB:NEOP) Cardinal Health Exclusive agreement to market and distribute Lymphoseek, a radioactive lymphatic mapping targeting agent in Phase III trials in breast cancer and melanoma Cardinal Health will have U.S. rights to distribute Lymphoseek for an initial term of five years following marketing clearance from the FDA (11/27)
Novelos Therapeutics Inc. (OTC BB:NVLT) Lee's Pharmaceutical Holdings Ltd. Exclusive licensing agreement for certain Asian commercialization rights for NOV-002 in cancer and NOV-205 in hepatitis Novelos will receive undisclosed up-front and milestone payments, as well as double-digit royalties, while Lee's will cover the costs of development and marketing in China (12/18)
PDL BioPharma Inc. (PDLI) Otsuka Pharmaceutical Co. Ltd. (Japan) Agreement for PDL to sell rights to its marketed product, IV Busulfex, to Otsuka for $200M in cash The oncologic product is marketed in the U.S. and Canada (12/17)
Santarus Inc. (SNTS) GlaxoSmithKline plc (UK) Marketing deals for commercialization rights to prescription and over-the-counter immediate-release omeprazole proton pump inhibitor products in up to 114 countries excluding the U.S., Europe, Australia, Japan and Canada, as well as rights to branded Zegerid products in Puerto Rico and the U.S. Virgin Islands Santatus stands to receive an $11.5M up-front fee and tiered, double-digit royalties (12/3)
Sciele Pharma Inc. (SCRX) Novo Nordisk Inc. (Denmark) Exclusive agreement to market Prandin, an oral glucose-lowering treatment used to manage Type II diabetes Sciele exclusively will market Prandin and potentially PrandiMet in the U.S.; it also will have the right of first refusal for marketing rights in the U.S. to other Novo Nordisk products contaning repaglinide (11/19)
TheraQuest Biosciences Inc.* Wonpung Mulsan Co. Ltd. (South Korea) Licensing agreement granting Wonpung rights in Asia to two of TheraQuest's products and right of first refusal in Asia for an additional five products TheraQuest received a $1.5M equity investment and $1.5M in licensing fees; Wonpung also may make an additional $1.5M equity investment in 2008 (12/18)
Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange.